Literature DB >> 29851287

The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: An observational population-based study.

Z Liu1, Q Yang2, O Shi3, W Ye4, X Chen5,6, T Zhang1.   

Abstract

Viral hepatitis is a major public health concern in China, but data on national epidemiological characteristics are lacking. We collected reporting incidence data on hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in China from 2004 to 2014. Empirical mode decomposition (EMD) was performed to accurately describe the reporting incidence trends of HBV and HCV. A mathematical model was used to estimate the relative change in incidence across provinces and age groups. Nationwide, a total of 916 426 hepatitis B cases and 39 381 hepatitis C cases were recorded in 2004; the reporting incidences of HBV and HCV were 70.50/100 000 and 3.03/100 000, respectively. The overall relative changes in HBV and HCV reporting incidences in China from 2004 to 2014 were 0.98 (95% CI 0.96-1.00, P = .082) and 1.16 (95% CI 1.12-1.20, P < .001), respectively. Thirteen provinces experienced decline in HBV reporting incidence. Most provinces exhibited an increasing trend in HCV reporting incidence. People aged ≤24 displayed a significant descending trend in HBV reporting incidence; people aged ≥55 exhibited a significant increasing trend. For HCV infection, the reporting incidence increased in all age groups except the 10-14 age group. In China, the majority of provinces have experienced decline or remained stable in HBV infection but show significant increases in HCV infection. Children and adolescents are well protected from HBV infection, while relatively higher increasing rates are found among older people. HCV is much more prevalent among older people, although its emergence has shifted to younger age groups.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HBVzzm321990; China; HCV; incidence

Mesh:

Year:  2018        PMID: 29851287     DOI: 10.1111/jvh.12938

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  17 in total

Review 1.  Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives.

Authors:  Zeyu Zhao; Meijie Chu; Yichao Guo; Shiting Yang; Guzainuer Abudurusuli; Roger Frutos; Tianmu Chen
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

2.  Secular Trend of Cancer Death and Incidence in 29 Cancer Groups in China, 1990-2017: A Joinpoint and Age-Period-Cohort Analysis.

Authors:  Xiaoxue Liu; Maigeng Zhou; Fang Wang; Sumaira Mubarik; Yafeng Wang; Runtang Meng; Fang Shi; Haoyu Wen; Chuanhua Yu
Journal:  Cancer Manag Res       Date:  2020-07-23       Impact factor: 3.989

3.  Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China.

Authors:  Huan Xia; Chengzhen Lu; Yin Wang; Silvere D Zaongo; Yue Hu; Yue Wu; Zhongfang Yan; Ping Ma
Journal:  Front Pharmacol       Date:  2020-05-19       Impact factor: 5.810

4.  Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: a randomized controlled trial protocol.

Authors:  William C W Wong; Nancy S Yang; Jingjing Li; Hang Li; Eric Y F Wan; Thomas Fitzpatrick; Yuan Xiong; Wai-Kay Seto; Polin Chan; Ruihong Liu; Weiming Tang; Joseph D Tucker
Journal:  BMC Public Health       Date:  2020-07-02       Impact factor: 3.295

5.  Barriers to the Prevention and Control of Hepatitis B and Hepatitis C in the Community of Southwestern China: A Qualitative Research.

Authors:  Tingting Li; Shu Su; Yong Zhao; Runze Deng; Mingyue Fan; Ruoxi Wang; Manoj Sharma; Huan Zeng
Journal:  Int J Environ Res Public Health       Date:  2019-01-15       Impact factor: 3.390

6.  The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017.

Authors:  Mimi Zhai; Jianhai Long; Sushun Liu; Chun Liu; Li Li; Leping Yang; Yamin Li; Bo Shu
Journal:  Aging (Albany NY)       Date:  2021-01-12       Impact factor: 5.682

7.  Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES).

Authors:  Hui Wang; Xin-Zu Chen; Xiao-Long Chen; Wei-Han Zhang; Kai Liu; You-Juan Wang; Huai-Rong Tang; Jian-Kun Hu
Journal:  Cancer Med       Date:  2021-05-02       Impact factor: 4.452

8.  Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis.

Authors:  Huan Xia; Yaping Zhang; Silvere D Zaongo; Jing Liang; Xiaowen Gong; Yue Hu; Ping Ma; Fengmei Wang
Journal:  Ann Transl Med       Date:  2021-05

9.  Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China.

Authors:  Zhenqiu Liu; Xianhua Mao; Yanfeng Jiang; Ning Cai; Li Jin; Tiejun Zhang; Xingdong Chen
Journal:  Cancer Med       Date:  2019-08-06       Impact factor: 4.452

10.  Changes in epidemiological features of vaccine preventable infectious diseases among three eras of national vaccination strategies from 1953 to 2018 in Shanghai, China.

Authors:  Qiangsong Wu; Maryam Zaid; Zeliang Xuan; Chenxi Wang; Haiyan Gu; Min Shi; Jiahui Zhu; Yi Hu; Jingyi Liu
Journal:  Lancet Reg Health West Pac       Date:  2021-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.